Hanson Pharmaceuticals (03692) rose more than 5%. As of press release, it rose 5.24% to HK$15.66, with a turnover of HK$38.288 million.
The Zhitong Finance App learned that Hanson Pharmaceuticals (03692) rose by more than 5%. As of press release, it had risen 5.24% to HK$15.66, with a turnover of HK$38.288 million.
According to the news, Hanson Pharmaceuticals announced its 2023 results, with revenue of about $10.104 billion, up 7.7% year on year; R&D expenses of about $2,097 billion, up 23.8% year on year; net profit of $3,277.5 billion, up 26.85% year on year; basic profit per share of 0.55 yuan, with a final dividend of HK14.22 cents per share, or HK5 cents over the same period last year.
During the period, the Group approved a total of 6 new products for marketing, including an innovative drug (including approval for 2 indications); 23 new declarations and clinical approvals were obtained, which are related to 10 innovative drugs. The sales revenue of innovative drugs and cooperative products was about 6.865 billion yuan, accounting for about 67.9% of revenue, which has become the core driving force for the sustainable growth of the company's performance.